Skip to main content
. 2019 Sep 22;59(10):1762–1772. doi: 10.1111/head.13642

Figure 3.

Figure 3

Migraine‐related disabilitya among respondents endorsing efficacy and/or safety domains. aAs determined using the Migraine Disability Assessment (MIDAS), where score 0‐5 = grade I (little or no disability), 6‐10 = grade II (mild disability), 11‐20 = grade III (moderate disability), and ≥21 = grade IV (severe disability).